JPRN-UMIN000000857已完成2 期
Docetaxel and S-1 as adjuvant chemotherapy for pathological stage II, IIIA, IIIB gastric cancer - Docetaxel and S-1 as adjuvant chemotherapy
Dept. of Surgery and Science, Kyushu University0 个研究点目标入组 20 人开始时间: 2007年10月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix. 2. Contraindication to S-1 3. Under treatment with flucytosine, phenytoin, or warfarin 4. Past history of severe drug hypersensitivity. 5. Uncontrolled medical conditions (e.g., Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X-ray, malignant hypertension, congestive heart failure, myocardial infarction in previous 6 months, arrhythmia requiring treatment, hemorrhage, diabetes). 6. Hepatitis B/C 7. Diarrhea 8. Pregnant or lactating women and women of child bearing potential not using contraception 9. Severe peripheral edema. 10. Grade 2 or greater peripheral neuropathy. 11. HIV positive. 12. Patients judged by the investigator as unfit to be enrolled in the study.
研究者
相似试验
已完成
不适用
eo adjuvant chemotherapy by Docetaxel + S-1 for resentable gasric cabcergastric cancerJPRN-UMIN000015632Department of Frontier Surgery, Graduate school of Medicine, Chiba University20
已完成
不适用
Adjuvant chemotherapy combined with docetaxel and cyclophosphamide for Japanese breast cancer patients without lymph node metastasis or with three and under lymph node metastasis.Breast cancerJPRN-UMIN000002310Gunma Breast Cancer Research Group 2 surgery90
已完成
2 期
Docetaxel and S-1 treatment for patients with metastatic breast cancerJPRN-jRCT1091220030Kobe Breast cancer Oncology Group (KBCOG)40
进行中（未招募）
1 期
eoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer - EXPRESSIOEligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC.MedDRA version: 14.1Level: PTClassification code 10006201Term: Breast cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006200Term: Breast cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-006381-29-DEniversitätsmedizin Mainz200
已完成
1 期
Phase I study of Docetaxel, Cisplatin and S-1 in patients with advanced or recurrent gastric cancerGastric cancerJPRN-UMIN000000978Shizuoka Cancer Center18